BiologicalDrug
Vilamakitug clinical trials
- studies test it
- 3
- open now
- 1
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the vilamakitug studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vilamakitug is read from its arms, and is right about nine times in ten.
Testing it · 3
- Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for EfficacyNot yet recruitingPhase 2XBiotech, Inc.NCT06526377Written as vilamakitug
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic CancerCompletedPhase 1/2XBiotech, Inc.NCT04825288Written as Phase I: XB2001 250 mg
- Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, FluoropyrimidineActive, not recruitingPhase 1/2Centre Georges Francois LeclercNCT05201352Written as trifluridine/tipiracil + XB2001
Codes
What other systems call vilamakitug · ClinicalTrials.gg INT014589
- UNII (FDA) 3562YZ5W3HVILAMAKITUGOne source FDA
- NCI Thesaurus C180521VilamakitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3562YZ5W3H | VILAMAKITUG | One source FDA |
| NCI Thesaurus | C180521 | Vilamakitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.